Insider Trading Alert - Illumina And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Sept. 6, 2013, 132 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $13.05 to $156,271,000.00.

Highlighted Stocks Traded by Insiders:

Illumina (ILMN) - FREE Research Report

Walt David R who is Director at Illumina sold 5,000 shares at $77.18 on Sept. 6, 2013. Following this transaction, the Director owned 931,488 shares meaning that the stake was reduced by 0.53% with the 5,000 share transaction.

The shares most recently traded at $79.73, up $2.55, or 3.2% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 25,062
  • 24-Week # shares sold: 55,383

The average volume for Illumina has been 1.0 million shares per day over the past 30 days. Illumina has a market cap of $9.9 billion and is part of the health care sector and drugs industry. Shares are up 42.96% year to date as of the close of trading on Friday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 92.4. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

IPOs That Should Be on Your Radar

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement